

Company Number: 417625

Flanagan Berkley Road Pharmacy Ltd
Abridged Unaudited Financial Statements
for the financial year ended 28 February 2025

Flanagan Berkley Road Pharmacy Ltd
CONTENTS

	Page
Statement of Financial Position	3
Notes to the Financial Statements	4 - 8

Flanagan Berkley Road Pharmacy Ltd
STATEMENT OF FINANCIAL POSITION

as at 28 February 2025

	Notes	2025 €	2024 €
Non-Current Assets			
Property, plant and equipment	7	<u>970,540</u>	<u>989,194</u>
Current Assets			
Inventories	8	138,645	148,832
Receivables	9	177,708	223,244
Cash and cash equivalents		<u>40,526</u>	<u>27,756</u>
		<u>356,879</u>	<u>399,832</u>
Payables: amounts falling due within one year	10	<u>(307,863)</u>	<u>(365,133)</u>
Net Current Assets		<u>49,016</u>	<u>34,699</u>
Total Assets less Current Liabilities		<u>1,019,556</u>	<u>1,023,893</u>
Payables:			
amounts falling due after more than one year	11	<u>(303,691)</u>	<u>(341,723)</u>
Net Assets		<u><u>715,865</u></u>	<u><u>682,170</u></u>
Equity			
Called up share capital presented as equity		100	100
Retained earnings		<u>715,765</u>	<u>682,070</u>
Equity attributable to owners of the company		<u><u>715,865</u></u>	<u><u>682,170</u></u>

I as Director of Flanagan Berkley Road Pharmacy Ltd, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 20 November 2025 and signed on its behalf by:

Brendan Flanagan
Director

Flanagan Berkley Road Pharmacy Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

1. General Information

Flanagan Berkley Road Pharmacy Ltd is a company limited by shares incorporated in Ireland. 9 Brews Hill, Navan, Co Meath, Ireland is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Director's Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 28 February 2025 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102). These are the company's first set of financial statements prepared in accordance with FRS 102

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

Cash flow statement

The company has availed of the exemption in FRS 102 from the requirement to prepare a Statement of Cash Flows because it is classified as a small company.

Revenue

Turnover represents the total invoice value, excluding value added tax, of sales made during the year.

Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	
Long leasehold property	-	5% Straight line
Fixtures, fittings and equipment	-	12.5% Reducing balance
Motor vehicles	-	15% Straight Line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Inventories

Inventories are valued at the lower of cost and net realisable value. Inventories are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing inventories to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other receivables

Trade and other receivables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Flanagan Berkley Road Pharmacy Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other payables

Trade and other payables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Statement of Financial Position date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income Statement.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging:		
Depreciation of property, plant and equipment	18,654	18,658
	<u> </u>	<u> </u>
4. Finance costs	2025	2024
	€	€
Interest	15,431	16,784
	<u> </u>	<u> </u>

Flanagan Berkley Road Pharmacy Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

5. Employees

The average monthly number of employees, including director, during the financial year was 5, (2024 - 5).

	2025 Number	2024 Number
Assistants	4	4
Directors	1	1
	<u>5</u>	<u>5</u>

6. Tax on profit

	2025 €	2024 €
(a) Analysis of charge in the financial year		
Current tax:		
Corporation tax at 12.50% (2024 - 12.50%) (Note 6 (b))	-	237
	<u>-</u>	<u>237</u>

(b) Factors affecting tax charge for the financial year

The tax assessed for the financial year differs from the standard rate of corporation tax in Republic of Ireland 12.50% (2024 - 12.50%). The differences are explained below:

	2025 €	2024 €
Profit taxable at 12.50%	<u>33,695</u>	<u>37,426</u>
Profit before tax multiplied by the standard rate of corporation tax in Republic of Ireland at 12.50% (2024 - 12.50%)	4,212	4,678
Effects of:		
Capital allowances for period in excess of depreciation	<u>(4,212)</u>	<u>(4,441)</u>
Total tax charge for the financial year (Note 6 (a))	<u>-</u>	<u>237</u>

7. Property, plant and equipment

	Land and buildings freehold €	Long leasehold property €	Fixtures, fittings and equipment €	Motor vehicles €	Total €
Cost					
At 1 March 2024	907,500	208,884	225,978	42,000	1,384,362
At 28 February 2025	<u>907,500</u>	<u>208,884</u>	<u>225,978</u>	<u>42,000</u>	<u>1,384,362</u>
Depreciation					
At 1 March 2024	-	184,685	205,233	5,250	395,168
Charge for the financial year	-	10,440	2,964	5,250	18,654
At 28 February 2025	<u>-</u>	<u>195,125</u>	<u>208,197</u>	<u>10,500</u>	<u>413,822</u>
Carrying amount					
At 28 February 2025	<u>907,500</u>	<u>13,759</u>	<u>17,781</u>	<u>31,500</u>	<u>970,540</u>
At 29 February 2024	<u>907,500</u>	<u>24,199</u>	<u>20,745</u>	<u>36,750</u>	<u>989,194</u>

Flanagan Berkley Road Pharmacy Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

8. Inventories	2025	2024
	€	€
Finished goods and goods for resale	138,645	148,832
	<u><u>138,645</u></u>	<u><u>148,832</u></u>
The replacement cost of stock did not differ significantly from the figures shown.		
9. Receivables	2025	2024
	€	€
Trade receivables	87,476	94,229
Other debtors	56,129	72,917
Director's current account	31,735	53,113
Taxation	2,368	2,985
	<u><u>177,708</u></u>	<u><u>223,244</u></u>
10. Payables	2025	2024
Amounts falling due within one year	€	€
Amounts owed to credit institutions	53,463	53,463
Trade payables	39,030	40,663
Amounts owed to connected parties (Note 15)	211,086	260,707
Taxation	-	4,774
Accruals	4,284	5,526
	<u><u>307,863</u></u>	<u><u>365,133</u></u>
11. Payables	2025	2024
Amounts falling due after more than one year	€	€
Bank loans	303,691	341,723
	<u><u>303,691</u></u>	<u><u>341,723</u></u>
Loans		
Repayable in one year or less, or on demand	53,463	53,463
Repayable between one and two years	53,463	53,463
Repayable between two and five years	160,374	160,374
Repayable in five years or more	89,854	127,886
	<u><u>357,154</u></u>	<u><u>395,186</u></u>
12. Income Statement	2025	2024
	€	€
At 1 March 2024	682,070	644,881
Profit for the financial year	33,695	37,189
	<u><u>715,765</u></u>	<u><u>682,070</u></u>
At 28 February 2025	715,765	682,070
	<u><u>715,765</u></u>	<u><u>682,070</u></u>
13. Capital commitments		
The company had no material capital commitments at the financial year-ended 28 February 2025.		

Flanagan Berkley Road Pharmacy Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

14. Director's remuneration	2025 €	2024 €
Remuneration	70,557	55,538
Pension contributions	18,661	16,339
	<u>89,218</u>	<u>71,877</u>

15. Related party transactions

The following amounts are due to other connected parties:

	2025 €	2024 €
Flanagan Clearwater In Store Pharmacy Limited	<u>211,086</u>	<u>260,707</u>

Brendan Flanagan a directors of the company is also directors of Flanagan Clearwater In Store Pharmacy Limited. At the 28th February 2025 Flanagan Clearwater In Store Pharmacy Limited is owed a balance of €211,086 by this company which is included in creditors under amounts due from a connected company.

In the opinion of the director these amounts arise in the ordinary course of business and the terms of the amounts due are in accordance with the terms ordinarily offered by the company.

16. Events After the End of the Reporting Period

There have been no significant events affecting the company since the financial year-end.

17. Approval of financial statements

The financial statements were approved and authorised for issue by the board on 20 November 2025.